一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肺腺癌与肺鳞状细胞癌之间肿瘤浸润 T 淋巴细胞亚群分布特征及预后价值的差异
英文原题：The differences in the distribution characteristics and prognostic value of tumor-infiltrating T lymphocyte subsets between lung adenocarcinoma and lung squamous cell carcinoma.
查看英文原题
The differences in the distribution characteristics and prognostic value of tumor-infiltrating T lymphocyte subsets between lung adenocarcinoma and lung squamous cell carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
LUAD 与 LUSC 之间 CD4+和 CD4+TIL 亚群的分布和平衡存在差异，其中 CD4/CD4+比值密切影响 LUAD 患者的预后，但由于 CD4+T 细胞的限制，其在 LUSC 患者中的预后价值相对较弱。
研究思路结论见上方概要
背景
肿瘤免疫微环境特征是影响免疫治疗疗效的重要因素，且TIL（肿瘤浸润淋巴细胞）亚群在不同类型肿瘤中的分布存在差异。本研究旨在比较肺腺癌（LUAD）与肺鳞状细胞癌（LUSC）中TIL的CD4+和CD4+ T细胞亚群分布及其临床意义。
方法
收集2020年10月至2022年10月在郑州大学第二附属医院接受手术的78例LUAD和56例LUSC患者的肿瘤组织，通过病理观察检测TIL水平，并通过流式细胞术检测TIL中CD4+、CD4+ T细胞亚群的比例及CD4+/CD4+比值。比较这些指标在LUAD和LUSC之间的差异，并分析其与临床病理特征及患者生存的相关性。
结果
LUAD与LUSC之间TILs水平无显著差异（P>0.05）。LUSC中CD4+/CD4+比值较低，CD4+ T细胞比例高于LUAD（均P<0.05）。在LUAD中，CD4+、CD4+ T细胞比例及CD4+/CD4+与肿瘤大小或TNM分期相关，而在LUSC中，仅CD4+和CD4+ T细胞比例与肿瘤大小、分化程度或TNM分期相关。在LUAD患者中，较高的CD4+、CD4+ T细胞比例和较低的CD4+/CD4+预示更长的生存期，高CD4+/CD4+（>1.04）是PFS和OS的独立危险因素（P<0.05）；在LUSC患者中，CD4+ T细胞、CD4+ T细胞比例及CD4+/CD4+比值与患者预后无相关性（P>0.05）。
展开英文摘要原文
BACKGROUND
The characteristics of tumor immune microenvironment are important factors affecting the efficacy of immunotherapy, and there are differences in the distribution of tumor-infiltrating lymphocyte (TIL) subsets in different types of tumors. This study aims to compare the distributions of cluster of differentiation (CD) 4+ and CD4+ T cell subsets of TILs and their clinical significance between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).
METHODS
The tumor tissues of 78 LUAD and 56 LUSC patients who underwent surgery at The Second Affiliated Hospital of Zhengzhou University between October 2020 and October 2022 were collected, TIL level were detected by pathological observation, and the proportions of CD4+, CD4+ T cell subsets and CD4+/CD4+ ratio in TILs were detected by flow cytometry. These indicators were compared between LUAD and LUSC, and their correlations with clinicopathological characteristics and patient survival were analyzed.
RESULTS
There was no significant difference in the TILs level between LUAD and LUSC (P>0.05). The CD4+/CD4+ ratio in LUSC was lower, and proportion of CD4+ T cells was higher than those in LUAD (all P<0.05). In LUAD, the proportions of CD4+, CD4+ T cells and CD4+/CD4+ were correlated with tumor size or tumor-node-metastasis (TNM) stage, while in LUSC, only the proportions of CD4+ and CD4+ T cells were correlated with tumor size, degree of differentiation or TNM stage. In LUAD patients, higher proportions of CD4+, CD4+ T cells and lower CD4+/CD4+ predicted longer survival, and high CD4+/CD4+ (>1.04) was an independent risk factor for PFS and OS (P<0.05); In LUSC patients, there was no correlation between the proportions of CD4+ T cells, CD4+ T cells and CD4+/CD4+ ratio, and patient prognosis (P>0.05).
CONCLUSIONS
There were differences in the distribution and balance of CD4+ and CD4+ TIL subsets between LUAD and LUSC, among which CD4/CD4+ ratio closely affected the prognosis of LUAD patients but had relatively weak prognostic value in LUSC patients due to the restriction of CD4+ T cells.
论文信息
- 作者
- Zhang Z、Zhang S、Xu Y、Liu X、Dong W
- 第一作者单位
- Department of Oncology Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Respiratory Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.China
- 通讯作者单位
- Department of Oncology Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.China
- 期刊
- Chinese clinical oncology2024 Dec
- 原文标识
- PubMed 39806849 · DOI 10.21037/cco-24-62